PL2707003T3 - Krystaliczne sole amidu kwasu (4s,4as,5ar,12as)-4-dimetyloamino-3,10,12,12a-tetrahydroksy-7-[(metoksy(metylo)amino)metylo]-1,11-diokso- 1,4,4a,5,5a,6,11,12a-oktahydronaftaceno- 2-karboksylowego i sposoby ich stosowania - Google Patents

Krystaliczne sole amidu kwasu (4s,4as,5ar,12as)-4-dimetyloamino-3,10,12,12a-tetrahydroksy-7-[(metoksy(metylo)amino)metylo]-1,11-diokso- 1,4,4a,5,5a,6,11,12a-oktahydronaftaceno- 2-karboksylowego i sposoby ich stosowania

Info

Publication number
PL2707003T3
PL2707003T3 PL12782600T PL12782600T PL2707003T3 PL 2707003 T3 PL2707003 T3 PL 2707003T3 PL 12782600 T PL12782600 T PL 12782600T PL 12782600 T PL12782600 T PL 12782600T PL 2707003 T3 PL2707003 T3 PL 2707003T3
Authority
PL
Poland
Prior art keywords
methyl
octahydronaftaceno
tetrahydroxy
dioxy
dimethylamino
Prior art date
Application number
PL12782600T
Other languages
English (en)
Polish (pl)
Inventor
Catherine Coulter
Sean M Johnston
Farzaneh Seyedi
Original Assignee
Paratek Pharm Innc
Allergan Pharmaceuticals Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc, Allergan Pharmaceuticals Int Ltd filed Critical Paratek Pharm Innc
Publication of PL2707003T3 publication Critical patent/PL2707003T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08Hydroxylamino compounds or their ethers or esters
    • C07C239/20Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/40Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/461,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12782600T 2011-05-12 2012-05-14 Krystaliczne sole amidu kwasu (4s,4as,5ar,12as)-4-dimetyloamino-3,10,12,12a-tetrahydroksy-7-[(metoksy(metylo)amino)metylo]-1,11-diokso- 1,4,4a,5,5a,6,11,12a-oktahydronaftaceno- 2-karboksylowego i sposoby ich stosowania PL2707003T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485179P 2011-05-12 2011-05-12
PCT/US2012/037838 WO2012155146A1 (en) 2011-05-12 2012-05-14 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
EP12782600.6A EP2707003B1 (en) 2011-05-12 2012-05-14 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same

Publications (1)

Publication Number Publication Date
PL2707003T3 true PL2707003T3 (pl) 2019-11-29

Family

ID=47139728

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12782600T PL2707003T3 (pl) 2011-05-12 2012-05-14 Krystaliczne sole amidu kwasu (4s,4as,5ar,12as)-4-dimetyloamino-3,10,12,12a-tetrahydroksy-7-[(metoksy(metylo)amino)metylo]-1,11-diokso- 1,4,4a,5,5a,6,11,12a-oktahydronaftaceno- 2-karboksylowego i sposoby ich stosowania

Country Status (15)

Country Link
US (4) US9255068B2 (https=)
EP (2) EP2707003B1 (https=)
JP (5) JP6574572B2 (https=)
CA (1) CA2835876C (https=)
CY (1) CY1127230T1 (https=)
DK (1) DK2707003T3 (https=)
ES (2) ES2739626T3 (https=)
HR (1) HRP20191295T8 (https=)
HU (1) HUE044536T2 (https=)
LT (1) LT2707003T (https=)
PL (1) PL2707003T3 (https=)
PT (1) PT2707003T (https=)
SI (1) SI2707003T1 (https=)
TR (1) TR201911086T4 (https=)
WO (1) WO2012155146A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8856782B2 (en) 2007-03-01 2014-10-07 George Mason Research Foundation, Inc. On-demand disposable virtual work system
US9098698B2 (en) 2008-09-12 2015-08-04 George Mason Research Foundation, Inc. Methods and apparatus for application isolation
US9255068B2 (en) * 2011-05-12 2016-02-09 Warner Chilcott Company, Llc Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
WO2013082437A1 (en) 2011-12-02 2013-06-06 Invincia, Inc. Methods and apparatus for control and detection of malicious content using a sandbox environment
CA2873412A1 (en) * 2012-05-14 2013-11-21 Paratek Pharmaceuticals, Inc. Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
HUE066360T2 (hu) * 2016-10-19 2024-07-28 Tetraphase Pharmaceuticals Inc Eravaciklin kristályformái
CN111343991A (zh) * 2017-07-21 2020-06-26 阿尔米雷尔有限责任公司 非炎性病变的治疗
AU2019248350B2 (en) * 2018-04-06 2023-07-27 Almirall, Llc Process for making sarecycline hydrochloride
JP7840880B2 (ja) * 2020-06-11 2026-04-06 パラテック ファーマシューティカルズ,インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
US12487293B2 (en) 2021-06-14 2025-12-02 Hioki E.E. Corporation Short circuit detection device and short circuit detection method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (https=) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
DK0599397T3 (da) 1992-11-17 1996-09-16 Univ New York State Res Found Tetracycliner, herunder non-mikrobielle, kemisk-modificerede tetracycliner, inhiberer overdreven collagentværbinding ved diabetes
WO1995022529A1 (en) 1994-02-17 1995-08-24 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
CA2892739A1 (en) * 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2008079339A2 (en) 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
CA2717703A1 (en) * 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof
TWI680117B (zh) * 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
US9255068B2 (en) * 2011-05-12 2016-02-09 Warner Chilcott Company, Llc Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
CA2873412A1 (en) * 2012-05-14 2013-11-21 Paratek Pharmaceuticals, Inc. Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide

Also Published As

Publication number Publication date
HRP20191295T1 (hr) 2019-10-18
HRP20191295T8 (hr) 2020-02-07
CA2835876A1 (en) 2012-11-15
CA2835876C (en) 2020-04-14
JP6574572B2 (ja) 2019-09-11
EP2707003A4 (en) 2014-11-12
US20200024223A1 (en) 2020-01-23
LT2707003T (lt) 2019-10-10
EP3574908B1 (en) 2024-07-31
JP2019142867A (ja) 2019-08-29
JP6876082B2 (ja) 2021-05-26
EP3574908B8 (en) 2024-09-11
DK2707003T3 (da) 2019-08-05
EP2707003B1 (en) 2019-05-01
JP2014520077A (ja) 2014-08-21
JP2023093519A (ja) 2023-07-04
ES2739626T3 (es) 2020-02-03
JP2021098695A (ja) 2021-07-01
JP2017132775A (ja) 2017-08-03
US20190040002A1 (en) 2019-02-07
PT2707003T (pt) 2019-08-05
WO2012155146A1 (en) 2012-11-15
HUE044536T2 (hu) 2019-10-28
EP3574908A1 (en) 2019-12-04
SI2707003T1 (sl) 2019-10-30
EP2707003A1 (en) 2014-03-19
CY1127230T1 (el) 2026-02-25
ES2985493T3 (es) 2024-11-06
US20130012480A1 (en) 2013-01-10
US20160200671A1 (en) 2016-07-14
TR201911086T4 (tr) 2019-08-21
US9255068B2 (en) 2016-02-09

Similar Documents

Publication Publication Date Title
PL2707003T3 (pl) Krystaliczne sole amidu kwasu (4s,4as,5ar,12as)-4-dimetyloamino-3,10,12,12a-tetrahydroksy-7-[(metoksy(metylo)amino)metylo]-1,11-diokso- 1,4,4a,5,5a,6,11,12a-oktahydronaftaceno- 2-karboksylowego i sposoby ich stosowania
HRP20181996T1 (hr) Ne-integrirajući lentiviralni vektori
EP2661591A4 (en) EJEKTORZYKLUS
IL222748A (en) 6-acyl-1,2,4-triazine-3,5-dione derivative and herbicides comprising it
PT3320912T (pt) Imunoterapia à base de indoleamina 2,3-dioxigenase
EP2754205A4 (en) OVERLAPPING AND PLACED GROUP ANTENNAS
EP2753633A4 (en) PROTEIN-CONTAINING LUBRICANTS, THEIR PREPARATION AND USE
HRP20150926T1 (xx) Pripravci u krutom stanju
EP2782589A4 (en) ANTIMICROBIAL PEPTIDES AND METHOD FOR THEIR USE
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
PL2758371T3 (pl) Nowe tiopochodne niosące laktamy jako silne inhibitory hdac i ich zastosowania jako leki
FI20086250A0 (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
IL225342A0 (en) Soy adhesives and composites made from the adhesives
EP2672981A4 (en) MULTIPARTICULAR L-MENTHOL FORMULATION AND CORRESPONDING METHODS
ITUD20120072A1 (it) "dispositivo di fissaggio pneumatico modulare"
FR2973218B1 (fr) Plaque d'osteosynthese.
FR2968601B1 (fr) Pneumatique ayant des bourrelets perfectionnes.
SG11201401565TA (en) Novel 1,1,1,4,4,5,5,6,6,6-decafluorohex-2-ene isomer mixtures and uses thereof
PL2565182T3 (pl) Nowa pochodna amidu i jej zastosowanie jako leku
BR302012001179S1 (pt) "configuração aplicada em farol"
BR112014009953A2 (pt) método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
BR112013014299A2 (pt) fixador entalhado
EP2475430A4 (en) GRANULATED ANTHELMINTIC PREPARATIONS AND OUTPUT SYSTEMS THEREFOR
BR112014000232A2 (pt) primeira composição, segunda composição e artigo
FR2961128B1 (fr) Pneumatique ayant des bourrelets perfectionnes.